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AN INVESTIGATION INTO THE PERFORMANCE OF THE PARADNA® 
SYSTEMS BODY FLUID ID TEST ON SEMEN SAMPLES 
KAYLEE TAYLOR PARADIS 
ABSTRACT 
 Recent research efforts in the field of forensic biology include development of a 
confirmatory one-step testing methodology for biological fluids. Such techniques that 
have been shown to be promising include the analysis of deoxyribonucleic acid (DNA) or 
messenger ribonucleic acid (mRNA) contained within the specialized cells of specific 
body fluids. In current forensic practice, the possible biological origin of an evidentiary 
item or stain is often evaluated using protein-based presumptive testing. Ribonucleic acid 
(RNA) is an effective marker for the identification of body fluids because it codes for 
those specific proteins within the particular cells that make up each fluid. LGC has 
developed the ParaDNA® Body Fluid ID test that detects specific RNA markers allowing 
discrimination of six different body fluids. This research focuses on PRM2 and SEMG1, 
indicative of spermatozoa and seminal fluid, respectively. The ParaDNA® Body Fluid 
ID test was investigated to evaluate its performance with forensic semen samples and to 
determine if it is advantageous over current conventional semen screening methodology. 
Factors such as sensitivity, PRM2 and SEMG1 stability in aged stains at room 
temperature and in semen subjected to multiple freeze-thaw cycles, and performance on 
post-coital swabs were evaluated. Both spermatozoa and seminal fluid were detected in 
one of six 1:10 diluted stains tested and zero of six 1:50 diluted stains. Conventional 
semen screening methodology detected both components in six trials of 1:10 and 1:50 
  vi 
stains. PRM2 and SEMG1 were detected in stains prepared with neat liquid semen 
subjected up to 10 freeze-thaw cycles, in room temperature stains stored for up to 101 
days, as well as in three different post-coital swabs. Of the 82 samples run on the 
instrument, 22 were false negatives, with a majority of them occurring during the 
sensitivity study with diluted stains, indicating the ParaDNA® Body Fluid ID Test is not 
yet suitable to replace current conventional screening methods. Upon further validation it 
could serve as a valuable tool for forensic laboratories. 
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1. INTRODUCTION 
1.1 Prevalence of Sexual Assault Cases and the Importance of Semen Evidence  
 According to the Bureau of Justice Statistics, there were 323,450 cases of rape 
and sexual assault in the United States in 2016, and victimization surveys indicate that 
only approximately 23% of these violent crimes were reported that same year [1]. 
Extensive psychological research has attempted to determine the reasons sexual assault 
victims have for not reporting a crime. Some of these reasons include self-blame for the 
incident, the victim knew the perpetrator, and negative reactions from professionals, 
friends, and family that cause the victim to question if they were really assaulted [2-4]. 
Research has also sought to discover the reasons that encourage victims to report rape 
and sexual assault since early reporting can quicken an investigation. One such reason is 
that victims are confident in their ability to withstand the criminal investigation because 
of the forensic evidence collected against the perpetrator [5].  
Forensic evidence from sexual assault cases can come in a variety of forms. In 
some instances, evidence is collected at the crime scene, including hairs/pubic hairs, 
fibers, condoms, or semen stains collected with a collection device, such as a cotton 
swab. Evidence can also be collected as part of a sexual assault kit during a medical 
examination performed by a forensic nurse. During this examination, common pieces of 
evidence collected may include oral, vaginal, body, penile, and anal swabs, the victim’s 
clothing, and loose hairs or fibers [6]. While all of these types of evidence may be helpful 
in a criminal investigation, it is ultimately semen evidence that can either form a virtually 
direct linkage between a victim and a suspect or exclude a suspect because of the 
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presence of deoxyribonucleic acid (DNA) within the spermatozoa [7].  The fact that rape 
and sexual assault victims possess a sense of confidence due to the presence of forensic 
evidence and the potential weight such evidence may have in an investigation illustrate 
the importance of semen detection and analysis in these types of criminal cases.  
 
1.2 Detection and Analysis of Semen 
 Semen is composed of two fundamental parts: sperm cells, also referred to as 
spermatozoa, and seminal fluid [8]. The sperm cells contain DNA and therefore are 
important to detect during the analysis of semen evidence, as it can lead to downstream 
DNA testing and possibly the identification of a suspect. The seminal fluid contains a 
number of analytes that are found in relatively higher concentrations in semen than any 
other fluid or tissue in the body, and thus are often used as markers in current analysis of 
suspected semen stains [8].  
 Acid phosphatase (AP) is an enzyme that catalyzes the hydrolytic removal of an 
ester-linked phosphate group from any number of monophosphate substrates. AP occurs 
naturally in semen, which allows for its use when analyzing evidence for potential semen 
exposure [8]. There are two types of acid phosphatase: seminal acid phosphatase (SAP), 
found in the seminal fluid, and vaginal acid phosphatase (VAP), present in vaginal 
secretions [9]. SAP is produced in the epithelial cells located within the ducts inside the 
prostate gland and is secreted into the seminal fluid when the prostate gland contracts 
during ejaculation [8, 9]. For this reason, seminal acid phosphatase is the type of acid 
phosphatase of interest during semen detection. The detection of acid phosphatase is only 
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a presumptive indication of the presence of semen and must be followed up with 
subsequent, more specific testing. A common presumptive test for the chemical 
indication of acid phosphatase is a colorimetric assay that contains alpha-naphthyl 
phosphate and a diazonium salt. The enzymatic activity of AP facilitates the removal of a 
phosphate group from the naphthyl phosphate. This free naphthol combines with the 
colorless diazonium salt, such as Fast Blue B, to yield a color change that indicates a 
positive result for the chemical indications of acid phosphatase [10]. SAP can also be 
found in low concentrations in the blood of healthy males [11]. Although this test is 
effective in the presumptive indication of SAP, it is unable to distinguish SAP from VAP 
due to high similarity in molecular structure and substrate specificities, which is a 
disadvantage when analyzing sexual assault evidence such as vaginal swabs [12]. A 
secondary screening test or confirmatory method is therefore always performed after a 
positive presumptive test with the AP Spot test. 
  Secondary screening techniques for the detection of semen target both 
spermatozoa and other components found in seminal fluid. Another component found in 
seminal fluid is a glycoprotein known as prostate-specific antigen (PSA), or Protein P-30 
(P-30), that is produced in the prostate epithelium and secreted into the semen [8, 9]. PSA 
is commonly detected using lateral flow chromatographic immunoassay cartridges that 
utilize the antigenic properties of PSA to detect its presence. Anti-human PSA antibodies 
conjugated to a dye are present in the sample region of the cartridge. A sample extract is 
added, and if the sample contains PSA, these antibodies bind to the PSA antigens within 
the sample, forming a complex that migrates up the cartridge to the test line. Additional 
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antihuman PSA antibodies present on the test line bind to the complex migrating up the 
strip, making the dye visible, thus indicating a positive result [13]. PSA has also been 
found in detectable amounts in urine, breast milk, and the blood of healthy males [14-16].  
 Another component of seminal fluid that is tested for during semen detection is 
semenogelin (Sg), a protein that facilitates the formation of a gel matrix soon after 
ejaculation [8, 9]. Semenogelin is a more specific marker for semen than PSA as it has 
not been found to be in any other body fluid, but it is detectable in non-genital tissues 
such as skeletal muscle, the kidneys, and trachea [17]. Immunoassay cartridges that work 
very similarly to the mechanism previously described are also used to detect 
semenogelin.  
 While the presence of PSA or Sg is considered a strong indication for the 
presence of semen, those components can also be found in other tissues and fluids of the 
body [14-17]. Spermatozoa, however, are only found in semen [9]. Therefore, the most 
conclusive method to confirm the presence of semen is through microscopic examination 
of spermatozoa. This process involves the extraction of the suspected semen from the 
substrate into solution, centrifugation of the sample extract to isolate the sperm cells, and 
visualizing a portion of the resulting pellet on a microscope slide, usually with the aid of 
a chemical dye stain, such as Kernechtrot Picroindigocarmine (KPIC) Stain or the 
hematoxylin and eosin (H&E) stain [8, 9]. If sperm cells are observed during the 
microscopic examination, then no further analysis is required to prove that semen is 
present. If the examination is negative, that does not necessarily mean the stain in 
question is not semen. Instances that best illustrate this are cases where the perpetrator 
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has had a vasectomy and therefore no spermatozoa will be present in his ejaculate. There 
are also genetic conditions such as oligospermia, possessing an abnormally low sperm 
count, and azoospermia, where a male produces no sperm at all. For these reasons, a 
secondary screening test should always follow a positive AP test and a negative 
microscopic exam to minimize false negatives, as these sperm count conditions have no 
effect on seminal plasma constituents and their concentrations [8].  
 
1.3 The ParaDNA® Systems Body Fluid ID Test  
 Recent research efforts in the field of forensic biology include a confirmatory 
one-step testing methodology for biological fluids. Such techniques that have shown to 
be promising include the analysis of DNA or messenger ribonucleic acid (mRNA) within 
the specialized cells within particular body fluids [18-20]. Ribonucleic acid is an 
effective marker for the identification of body fluid because it codes for specific proteins 
within the particular cells that make up each fluid. The RNA marker SEMG1 targeted by 
the ParaDNA® Body Fluid ID Test (LGC, Teddington, Middlesex, UK) is used to detect 
seminal fluid as it codes for a major protein involved in the formation of a gel matrix that 
encapsulates spermatozoa after ejaculation [21]. The fundamental science behind the 
ParaDNA® Body Fluid ID Test is based on the detection, amplification, and analysis of 
the specific RNA markers within specialized cells to identify six bodily fluids: 
spermatozoa, seminal fluid, menstrual blood, saliva, peripheral blood, and vaginal 
secretions (Table 1).  
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Table 1. Six body fluids detected by the ParaDNA® Body Fluid ID Test and the 
corresponding RNA markers used to detect them 
Body Fluid RNA Marker 
Sperm Cells PRM2 
Seminal Fluid SEMG1 
Saliva HTN3 
Vaginal Fluid CYP2B7P1 
Menstrual Blood MMP10 
Peripheral Blood ALAS2 
 
In current forensic DNA testing laboratories, DNA is extracted from biological 
material found at a crime scene and amplified using a process known as Polymerase 
Chain Reaction (PCR). This process manipulates the naturally occurring mechanism that 
occurs during DNA replication at the cellular level to make an exponential amount of 
double-stranded copies of the targeted DNA segments specific for human identification 
[22]. These DNA segments of interest are tagged with a fluorescent DNA probe, which is 
used to monitor the progress of PCR, and are then separated based on their length by 
capillary electrophoresis to develop an interpretable profile.  
The ParaDNA® Systems instrument uses PCR to identify bodily fluids, but the 
process has some key differences compared to the parameters used during traditional 
DNA typing protocols. Because PCR is only designed to amplify DNA products, there is 
an extra step performed during the ParaDNA® Body Fluid ID Test to convert the RNA 
markers targeted by the kit into complementary DNA (cDNA) language so PCR can be 
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performed. This process is known as reverse transcription, where a reverse transcriptase 
enzyme is used to convert the RNA base sequence into a DNA base sequence [18]. After 
reverse transcription is completed, the analysis proceeds to an asymmetric PCR. In 
traditional symmetric PCR, the amplified products are double-stranded because of a 
relatively equal concentration of both the forward and reverse primer. With double-
stranded DNA products, only the labeled probe target sequences that successfully 
compete against the complementary strands to anneal to the target strand will fluoresce 
and therefore be detected [23]. In asymmetric PCR, the concentration of one of the 
primers is increased to favor amplification products of a single strand to improve the 
detectability of the fluorescent probe, and therefore the target of interest [23, 24].  
The ParaDNA® Systems Body Fluid ID Test utilizes HyBeacon® fluorescent 
probe technology. The probes are labeled with a fluorescent dye and are designed to 
target specific sequences within the RNA transcript to allow for amplification and 
identification of six target body fluids. After PCR, the test plate is heated so that any 
remaining double-stranded DNA products separate into single strands to permit probe 
binding. The system is then cooled to initiate the binding of the HyBeacon® probe to the 
target single-stranded DNA sequences. When the probe and DNA are annealed to one 
another, the labeled dye on the HyBeacon® probe fluoresces brightly. The annealing 
process is followed by a second heating phase, in which the DNA and probe will 
separate, and thus the probe will fluoresce less brightly. It is this change in fluorescence 
and the temperature at which it occurs that is measured and used to identify the body 
fluid in a sample [25].  
 * 8 
 The ParaDNA® Body Fluid ID Test plate appears as a square-like plate with four 
wells in the center that correspond to the four nibs or prongs on the sample collector 
when the device is placed into the test plate. Each well contains the reagents and primers 
required for body fluid identification. All six body fluid RNA markers are multiplexed, 
meaning that all six RNA target markers can be detected using different primers all at the 
same time. Upon completion of the run, the software generates a table with each body 
fluid and either a check (positive result) or a cross (negative result) for each (Figure 1). 
 
 
 
Figure 1. Image of results readout from one run on the ParaDNA® System with the 
Body Fluid ID Test. These results indicate a positive for both sperm cells and seminal 
fluid and negative results for the remaining fluids.  
 
 
1.4 Purpose of Study 
The goal of this research was to evaluate the ParaDNA® Systems Body Fluid ID Test 
and determine whether it is advantageous over conventional semen screening 
methodology. The following objectives were explored: 
i) the sensitivity of the test 
ii) the detectability of PRM2 and SEMG1  
a. in room temperature aged stains  
b. in semen subjected to up to ten freeze-thaw cycles  
iii) performance of the test on post-coital swabs were investigated.  
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2. MATERIALS AND METHODS 
2.1 Standard Sampling, Plate Preparation and Run Initiation for ParaDNA® Body 
Fluid ID Test 
Each ParaDNA® Body Fluid ID Test plate was removed from the freezer 
(approximately -20°C) and allowed to thaw for at least 15 minutes. Once thawed, each 
test plate was placed in a plate adapter supplied by LGC and spun in a plate spinner 
(Sorvall T1 Centrifuge, ThermoFisher Scientific, Waltham, MA, USA) at 3000 
revolutions per minute (rpm) for approximately 10 seconds. Dried stains were rubbed 
with the ParaDNA® Sample Collector in the closed position for 30-45 seconds. The 
collector was rotated so that all four nibs came into contact with the stain. After 
sampling, the sample collector was returned to open position and placed and sealed into 
the test plate (Figure 2). The test plate was then placed into the ParaDNA® Systems 
instrument, the run was labeled with a unique identifier, and the “Start” button was 
clicked on the computer software to initiate the run. 
 
 
 
 
 
 
 
 
 
Figure 2. Photograph of ParaDNA® Sample Collector illustrating placement of nibs 
into the test plate when sealing the plate 
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2.2 Preliminary Testing of Semen Using ParaDNA® Body Fluid ID Test 
 
 Neat semen stains (25 µL) were prepared on a white cotton swatch and run on the 
ParaDNA® Systems instrument using the ParaDNA® Body Fluid ID Test to ensure that 
both the seminal fluid and sperm markers were identifiable by the instrument. Sources 
included in-house samples, commercially purchased samples (Bioreclamation Inc., 
Westbury, NY), and fertility clinic specimens (New England Cryogenic Center, Inc., 
Newton, MA). Such testing for each source was accomplished by following the protocol 
described in section 2.1.  
 
2.3 Conventional Semen Screening Methodology  
The conventional semen screening methodology that was used in this study 
included presumptive screening for acid phosphatase using AP Spot Test reagent (SERI, 
Richmond CA, USA) and secondary screening for both semenogelin and prostate-
specific antigen using RSID™-Semen immunoassay cards (Independent Forensics, 
Lombard IL, USA) and ABACard® p30 immunoassay cards (Abacus Diagnostics, West 
Hills CA, USA), respectively. Confirmation was accomplished via microscopic 
examination with visualization of any spermatozoa present.  
 The AP Spot reagent was prepared by dissolving approximately 0.13 grams of AP 
Spot Test powder reagent in five milliliters (mL) of deionized water. Three separate 2 
mm x 2 mm cuttings of each stain were placed into separate wells of a spot plate. Ten 
microliters of AP Spot Test reagent was dispensed onto each cutting and the reaction was 
monitored for five minutes. Any violet color change that occurred prior to the five-minute 
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mark was considered a positive result, while no color change was considered a negative 
result.  
 Microscopic examination followed a positive AP Spot test and began with 
extracting three separate 5 mm x 5 mm cuttings per stain in 250 µL of water in a 2.0 mL 
microcentrifuge tube (Corning Inc, Corning, NY, USA) for approximately one hour. 
During the extraction time, the samples were gently mixed using an orbital shaker. 
Cuttings were then removed and placed into a filter-less Spin-X® Insert (Corning Inc, 
Corning, NY, USA), which was put back into the original 2.0 mL microcentrifuge tube 
and centrifuged at 13.2 rpm for 2 minutes. Cuttings and spin baskets were removed. 
Approximately 230 µL of the supernatant from each stain was removed and placed into 
separate 1.5 mL microcentrifuge tubes (Corning Inc, Corning, NY, USA) for testing with 
immunoassay cards. Three microliters of the pellet was heat fixed onto a clean 
microscope slide (Fisher Scientific, Hampton, NH, USA). All microscope slides were 
stained using KPIC. One drop of Nuclear Fast Red, or Christmas Tree Stain A (SERI, 
Richmond CA, USA), was placed onto each pellet sample for 15 minutes and gently 
washed with distilled water. One drop of picroindigocarmine, or Christmas Tree Stain B 
(SERI, Richmond CA, USA), was then added for one minute and gently washed with 
ethanol (Pharmco-AAPER, Brookfield, CT, USA). One drop of Cytoseal™60 (Richard 
Allen Scientific™, San Diego, CA, USA) was placed onto each coverslip (Fisher 
Scientific, Hampton, NH, USA), which was then positioned on top of each pellet sample. 
Pellet specimens were examined under a total magnification of 400x using a Nikon 
Eclipse E200 compound microscope (Nikon, Minato, Tokyo, JP). Samples were 
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considered to be confirmatory for the presence of semen if at least one sperm cell was 
identified, and negative if no sperm cells were observed.  
 To test for the presence of seminal fluid, the supernatant obtained from the 
extraction and centrifugation process was tested using the RSID™-Semen and 
ABACard® p30 immunoassay cards. Samples were tested with the RSID™-Semen 
cartridges according to manufacturer’s instructions [26]. First, 20 µL of supernatant was 
combined with 80 µL of the RSID™ Universal Buffer (Independent Forensics, Lombard 
IL, USA) for a total volume of 100 µL, all of which was pipetted into the test cartridge 
and results were read after 10 minutes. Samples were tested with the ABACard® p30 
cartridges by dispensing 200 µL of supernatant into the sample region and reading the 
result after 10 minutes, as instructed by the manufacturer [13]. Positive reactions for both 
immunoassay cards were determined by the presence of two lines, one in the test region 
and one in the control region of the cartridge, while a negative reaction was depicted by 
only one line in the control region.  
 
2.4 Sensitivity 
The sensitivity of the ParaDNA® Systems Body Fluid ID test was investigated 
using stains prepared with diluted semen. The same semen stain was tested using both the 
ParaDNA® Body Fluid ID test and the conventional semen screening method described 
previously and the results obtained were compared. The sensitivity aspect was divided 
into two parts based on differences in the preparation of the diluted semen stains and 
types of sources of semen samples included in the pooled stock solution and will be 
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designated as Sensitivity I and Sensitivity II hereafter. All liquid semen sources were kept 
frozen in between use and ranged in age from approximately 24 hours to three and a half 
years.   
 
2.4.1 Sensitivity I 
Four microliters of neat semen was collected from two in-house and one 
commercial source to form the pooled semen stock solution. A 100-µL solution of a 1:10 
dilution was prepared by adding 10 µL of the pooled neat semen to 90 µL of deionized 
water. This 1:10 dilution was used to prepare a serial dilution of 1:100 and 1:1000, both 
of which had a total volume of 100 µL. A 100-µL solution of a 1:50 dilution was 
prepared by adding 2 µL of the pooled neat semen into 98 µL of deionized water. This 
1:50 dilution was used to prepare serial dilutions of 1:250, 1:500, and 1:750, all of which 
had a total volume of 100 µL. 
One 25 µL stain per dilution was prepared on a cotton swatch and was tested for a 
total of three trials for both the ParaDNA® Body Fluid ID test and the conventional 
semen screening method. All three trials with the ParaDNA® system were completed 
first using the methodology described in 2.1. Conventional semen screening was then 
completed on the same stain using the procedure described in section 2.3.  
2.4.2 Sensitivity II 
Forty microliters of neat semen was collected from three separate in-house 
sources to create the pooled semen stock sample. A 1000-µL solution of a 1:10 dilution 
was prepared by adding 100 µL of the pooled neat semen into 900 µL of deionized water. 
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This 1:10 dilution was used to prepare a serial dilution of 1:100 and 1:1000, both of 
which had a total volume of 1000 µL. A 1000-µL solution of a 1:50 dilution was prepared 
by adding 20 µL of the pooled neat semen into 980 µL of deionized water. This 1:50 
dilution was used to prepare serial dilutions of 1:250, 1:500, and 1:750, all of which had a 
total volume of 1000 µL.  
One 50 µL stain per dilution was prepared on a cotton swatch and was tested for a 
total of three trials for both the ParaDNA® Body Fluid ID test and the conventional 
semen screening method. All three trials with the ParaDNA® system were completed 
first using the methodology described in section 2.1. Conventional semen screening was 
then completed using the procedure described in section 2.3.  
 
2.5 Aged Stains at Room Temperature 
To investigate the stability of the SEMG1 (seminal fluid) and PRM2 
(spermatozoa) RNA markers and the ParaDNA® Body Fluid ID Test’s ability to detect 
them, numerous 25 µL neat semen stains of the same donor were prepared on a cotton 
swatch and stored dry in a manila envelope away from light at room temperature for 
approximately four months. A separate stain was tested with the ParaDNA® Systems 
Body Fluid ID test every 5-9 days for 101 days using the protocol explained in section 
2.1. In some instances where one or both RNA markers tested negative, the stain was 
retested, and that result was also recorded.  
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2.6  Ten Freeze-Thaw Cycles 
  A fresh in-house sample that had never been frozen was acquired. Eleven 25 µL 
stains, designated as Day 0 stains, were prepared on a cotton swatch, allowed to dry and 
were stored at room temperature. Twenty-five microliters aliquots were pipetted into ten 
separate 1.5 mL centrifuge tubes and were kept frozen (-20°C). The remainder of the 
donated sample was pipetted into a 2.0 mL centrifuge tube and stored at the same 
temperature as the 10 aliquots (Figure 3). The same day that the eleven stains and ten 
aliquots were prepared, one of the Day 0 stains was tested on the ParaDNA® Systems 
Body Fluid ID test following the protocol described in section 2.1.  
 
 
 
 
 
 
 
Figure 3. Illustration of sample preparation for freeze-thaw study on Day 0 
On each testing day, one of the aliquots and the semen stock sample were thawed 
and used to prepare a 25-µL stain that was then tested with the ParaDNA® Body Fluid 
ID Test along with one of the Day 0 stains. This process was repeated every 3-8 days 
over an 89-day period for a total of 10 freeze-thaw cycles of the stock semen sample, ten 
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aliquots that only underwent 1 freeze-thaw cycle, and eleven stains that underwent zero 
freeze-thaw cycles.  
 
2.7 Post-Coital Swabs  
 The performance of the ParaDNA® Body Fluid ID test on mock case samples 
was assessed using three in-house post-coital vaginal swabs. Each of the three swabs was 
tested with the ParaDNA® Body Fluid ID Test for a total of three trials using the 
protocol outlined in section 2.1. Swabs were rubbed with the ParaDNA® Sample 
Collector for 45 seconds each trial. After testing with the ParaDNA® Systems 
instrument, each of the three samples was tested using the conventional semen screening 
method outlined in section 2.3 for a total of three trials. The results of the two methods 
were compared.  
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3. RESULTS 
Table 2. Results from preliminary semen testing. All stains were prepared with 25 µL 
of semen on a white cotton swatch.  
 
 
 
 
 
 
 
Source Type Result 
Sperm Cells Seminal Fluid 
Commercially Purchased  ✓ ✓ 
Commercially Purchased  ✓ ✖ 
Fertility Clinic Specimen  ✓ ✓ 
Fertility Clinic Specimen ✓ ✓ 
Fertility Clinic Specimen ✓ ✓ 
Fertility Clinic Specimen ✓ ✖ 
Fertility Clinic Specimen ✓ ✖ 
Obtained In-House  ✓ ✓ 
Obtained In-House  ✓ ✓ 
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Table 3. Conventional screening method and ParaDNA® Body Fluid ID Test for 
1:10 dilution in Sensitivity I 
 
 
 
 
 
 
 
 
 
 
 
Table 4. Conventional screening method and ParaDNA® Body Fluid ID Test for 
1:50 dilution in Sensitivity I 
 
 
 
 
 
 
 
 
 
 
  
 Trial 1 Trial 2 Trial 3 
AP Spot Test ✓ ✓ ✓ 
Microscopic Exam ✓ ✓ ✓ 
RSID™-Semen ✖ ✓ ✓ 
ABACard® p30 ✓ ✓ ✓ 
ParaDNA® 
Sperm ✓ ✓ ✓ 
Seminal 
Fluid 
✖ ✖ ✖ 
 Trial 1 Trial 2 Trial 3 
AP Spot Test ✓ ✓ ✓ 
Microscopic Exam ✓ ✓ ✓ 
RSID™-Semen ✖ ✖ ✖ 
ABACard® p30 ✓ ✓ ✓ 
ParaDNA® 
Sperm ✖ ✖ ✖ 
Seminal 
Fluid 
✖ ✖ ✖ 
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Table 5. Conventional screening method and ParaDNA® Body Fluid ID Test for 
1:10 dilution in Sensitivity II  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 6. Conventional screening method and ParaDNA® Body Fluid ID Test for 
1:50 dilution in Sensitivity II  
 
 
 
 
 
 
 
 
 
  
 Trial 1 Trial 2 Trial 3 
AP Spot Test ✓ ✓ ✓ 
Microscopic Exam ✓ ✓ ✓ 
RSID™-Semen ✓ ✓ ✓ 
ABACard® p30 ✓ ✓ ✓ 
ParaDNA® 
Sperm ✓ ✖ ✖ 
Seminal 
Fluid 
✓ ✖ ✖ 
 Trial 1 Trial 2 Trial 3 
AP Spot Test ✓ ✓ ✓ 
Microscopic Exam ✓ ✓ ✓ 
RSID™-Semen ✖ ✖ ✖ 
ABACard® p30 ✓ ✓ ✓ 
ParaDNA® 
Sperm ✖ ✖ ✖ 
Seminal 
Fluid 
✖ ✖ ✖ 
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Table 7. Detection of sperm (PRM2) and seminal fluid (SEMG1) in aged stains at 
room temperature 
Time Elapsed (days) Result Retested Stain 
0 ✓ ✓ - 
7 ✓ ✓ - 
14 ✓ ✓ - 
21 ✖ ✓ - 
30 ✓ ✓ - 
42 ✓ ✓ - 
58 ✓ ✖ - 
63 ✖ ✖ - 
65 ✓ ✓ 21* 
65 ✓ ✓ 58* 
72 ✓ ✓ - 
78 ✖ ✓ - 
78 ✓ ✓ 63* 
78 ✓ ✓ 78* 
85 ✓ ✓ - 
92 ✓ ✓ - 
101 ✓ ✓ - 
*Each negative result was retested. The right column lists the stain tested that was originally 
negative. 
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Table 8. Detection of PRM2 and SEMG1 in stains from zero to ten freeze-thaw 
cycles  
Time Elapsed (days) Sample Type Result Sperm Seminal 
0 Stain 0 ✓ ✓ 
7 
Stain 1 ✓ ✓ 
Freeze-thaw Cycle 1 ✓ ✓ 
14 
Stain 2 ✓ ✓ 
Aliquot 1 ✓ ✓ 
Freeze-thaw Cycle 2 ✓ ✓ 
21 
Stain 3 ✓ ✓ 
Aliquot 2 ✓ ✓ 
Freeze-thaw Cycle 3 ✓ ✓ 
27 
Stain 4 ✓ ✓ 
Aliquot 3 ✓ ✓ 
Freeze-thaw Cycle 4 ✓ ✓ 
35 
Stain 5 ✓ ✓ 
Aliquot 4 ✓ ✓ 
Freeze-thaw Cycle 5 ✓ ✓ 
42 
Stain 6 ✓ ✓ 
Aliquot 5 ✓ ✓ 
Freeze-thaw Cycle 6 ✓ ✓ 
49 
Stain 7 ✓ ✓ 
Aliquot 6 ✓ ✓ 
Freeze-thaw Cycle 7 ✓ ✓ 
77 
Stain 8 ✓ ✓ 
Aliquot 7 ✓ ✓ 
Freeze-thaw Cycle 8 ✓ ✓ 
81 
Stain 9 ✓ ✓ 
Aliquot 8 ✓ ✓ 
Freeze-thaw Cycle 9 ✓ ✓ 
84 
Stain 10 ✓ ✓ 
Aliquot 9 ✓ ✓ 
Freeze-thaw Cycle 10 ✓ ✓ 
89 Aliquot 10 ✓ ✓ 
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Table 9. Performance of ParaDNA® Body Fluid ID Test on Post-Coital Swab 1 
compared to conventional semen screening methodology 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 10. Performance of ParaDNA® Body Fluid ID Test on Post-Coital Swab 2 
compared to conventional semen screening methodology 
 
 
 
 
            
    
 
 
 
 
 
 
  
 
 
  
 Trial 1 Trial 2 Trial 3 
AP Spot Test ✓ ✓ ✓ 
Microscopic Exam ✓ ✓ ✓ 
RSID™-Semen ✓ ✓ ✓ 
ABACard® p30 ✓ ✓ ✓ 
ParaDNA® 
Sperm ✖ ✓ ✓ 
Seminal fluid ✖ ✓ ✓ 
Vaginal fluid ✖ ✖ ✖ 
 Trial 1 Trial 2 Trial 3 
AP Spot Test ✓ ✓ ✓ 
Microscopic Exam ✓ ✓ ✓ 
RSID™-Semen ✓ ✓ ✓ 
ABACard® p30 ✓ ✓ ✓ 
ParaDNA® Sperm ✓ ✓ ✓ 
Seminal fluid ✓ ✓ ✓ 
Vaginal fluid ✓ ✖ ✖ 
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Table 11. Performance of ParaDNA® Body Fluid ID Test on Post-Coital Swab 3 
compared to conventional semen screening methodology 
 
 
 
 
 
 
 
 
 
 
  
 Trial 1 Trial 2 Trial 3 
AP Spot Test ✓ ✓ ✓ 
Microscopic Exam ✓ ✓ ✓ 
RSID™-Semen ✓ ✓ ✓ 
ABACard® p30 ✓ ✓ ✓ 
ParaDNA® 
Sperm ✓ ✓ ✓ 
Seminal fluid ✓ ✓ ✓ 
Vaginal fluid ✓ ✓ ✓ 
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4. DISCUSSION 
4.1. Preliminary Testing of Semen Using ParaDNA® Body Fluid ID Test 
Of the two commercially purchased semen samples, only one donor yielded a 
positive result for both the sperm and seminal fluid RNA markers, while only three of the 
five fertility clinic samples yielded a fully positive result (Table 2). Interestingly, the 
sperm in these samples were motile after thawing, even after having been collected up to 
27 years prior. These five samples had been preserved with TEST-yolk buffer (TYB). 
TYB is a mixture of egg yolk, glycerol, gentamicin antibiotic and buffer solution [27]. 
Research has shown that TYB is an effective cryopreservation technique for the 
preservation of sperm morphology, chromatin stability and motility [27-29]. This may 
explain why in each fertility clinic semen sample there was a positive result for sperm, 
however, this does not explain why two of the five samples were negative for the seminal 
fluid marker. It is possible that although TYB may not affect the ParaDNA® System’s 
ability to detect the PRM2 sperm RNA marker, it may potentially influence its ability to 
detect the SEMG1 seminal fluid marker, as TYB only aims to preserve the sperm cells 
within a semen sample. These fertility clinic samples are also atypical in regards to 
forensic testing, as samples submitted for forensic testing have not been preserved for 
long-term storage. Based on this atypical sample nature and the inconsistency in results 
for the fertility clinic and commercial samples, these samples were not further utilized in 
the study.    
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4.2 Sensitivity Studies of the ParaDNA® Body Fluid ID Test Compared to 
Conventional Semen Screening Methodology  
 The goal of this portion of the study was to determine the ability of the 
ParaDNA® Body Fluid ID Test to detect the spermatozoa and seminal fluid RNA 
markers in diluted semen stains. Spermatozoa are detected by this mRNA-based assay 
through the amplification of the PRM2 marker. PRM2 codes for a specific protamine, 
which is a family of proteins that are responsible for the condensation and compaction of 
DNA within developing spermatozoa in many animal species, including humans [30, 31]. 
Seminal fluid is detected through the amplification of the SEMG1 marker, which codes 
for the semenogelin protein within the seminal fluid that is responsible for forming a gel 
matrix that encapsulates spermatozoa upon ejaculation [21]. A series of diluted semen 
stains were tested using the conventional semen screening methodology currently 
employed in forensic laboratories. This investigation was divided into two sections based 
on differences in the type of sample source, size of the stain, and the total volume used to 
prepare the serial semen dilutions.  
 The ParaDNA® Body Fluid ID Test was unable to detect the SEMG1 marker for 
seminal fluid in all three trials of the 1:10 dilution in the 25 µL stains in Sensitivity I, but 
it did detect the PRM2 marker for sperm in each trial (Table 3). However, neither RNA 
marker was detected in any of the three trials for the 1:50 dilutions (Table 4); therefore, 
no further dilutions were tested. When these same stains were tested using conventional 
semen screening methods, each trial for the 1:10 and 1:50 25 µL stains yielded a positive 
result for the AP Spot Test, the microscopic examination for sperm cells, and the 
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ABACard® p30 immunoassay card (Table 3, Table 4). RSID™-Semen immunoassay 
cards were also run on each sample. Two 1:10 samples tested positive with the RSID™-
Semen immunoassay while one tested negative (Table 3), and all three 1:50 trials tested 
negative (Table 4).  
 Similar trends were observed in Sensitivity II in that the conventional semen 
screening methodology was more sensitive to sperm and seminal fluid detection than the 
ParaDNA® Body Fluid ID Test. The ParaDNA® Body Fluid ID Test detected both the 
sperm and seminal fluid marker in the first 1:10 trial, but both markers dropped out for 
the second and third trial (Table 5). None of the 1:50 trials were positive for either 
marker (Table 6), and therefore no other dilutions were tested further. Considering the 
conventional screening methods, the AP Spot test, the microscopic examination, 
ABACard® p30 and RSID™-Semen immunoassay cards were positive for each of the 
three 1:10 trials (Table 5). The AP Spot test, the microscopic examination, and the 
ABACard® p30 cards were positive for all three trials of the 1:50 dilution, while the 
RSID™-Semen cards were negative for all three trials (Table 6). The results from 
Sensitivity I and II demonstrate how conventional semen screening techniques appear 
more sensitive in detecting sperm and seminal fluid in diluted stains than the ParaDNA® 
Body Fluid ID Test. In all six trials, conventional screening yielded accurate positive 
results 100% of the time for AP, PSA, and sperm, while ParaDNA® Body Fluid ID Test 
identified sperm and seminal fluid only once. Thus, if these were casework samples, all 
six would have been correctly identified as semen and processed for DNA based on 
conventional screening results, while only one of the six tested with the ParaDNA® Body 
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Fluid ID Test would have been recognized as semen and subjected to further testing. The 
validation data of the Para®DNA Body Fluid ID Test performed by LGC reports that 
spermatozoa and seminal fluid were detected in 50 µL stains down to the 1:500 dilution 
[32]. It is possible that diluted samples may be more difficult to detect with the body fluid 
identification test because the fluid soaks into the fibers of the substrate more readily and 
is not as easily retrievable by the sample collector [32]. 
 The results from Sensitivity I and II also demonstrated a significant difference in 
sensitivity between the RSID™-Semen and ABACard® p30 immunoassay cards. This 
could be explained by the drastic difference in test protocol provided by the 
manufacturers. The protocol for the RSID™-Semen immunoassay card instructs the user 
to dilute 20 µL of supernatant into 80 µL of the provided buffer before adding all 100 µL 
into the cartridge [26]. In contrast, the ABACard® p30 card instructions are to dispense 
200 µL of supernatant directly into the cartridge, thus resulting in a 10-fold difference in 
volume [13]. It is also possible that storage of the liquid semen samples in the freezer had 
an impact on the RSID™-Semen immunoassay card’s ability to detect semenogelin. It 
has been shown that RSID™-Semen was unable to detect semenogelin in a 1:4 dilution 
of post-vasectomized semen stored at approximately -15°C, while ABACard® p30 
detected PSA in the same frozen samples up to the 1:512 dilution [33]. This discrepancy 
could also be explained by potential inter-donor variation in Sg and PSA concentrations. 
4.3 Aged Stains at Room Temperature 
 The goal of this study was to investigate the ability of the ParaDNA® Body Fluid 
ID Test to detect the RNA markers specific to sperm cells and seminal fluid in room 
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temperature aged stains. In this experiment, a new 25 µL stain from one in-house donor 
stored at room temperature was tested every 5-9 days for 101 days using the ParaDNA® 
Body Fluid ID Test. In some instances, the test did not detect one or either of the two 
RNA markers. These days included Day 21, 58, 63, and 78 (Table 7). On days 21, 63, 
and 78 the PRM2 marker was undetectable yielding a negative result for sperm. Upon 
retest of these stains on day 65, 78 and 78, respectively, PRM2 was detected. On day 58 
and 63, marker SEMG1 was undetected, yielding a negative result for seminal fluid, but 
upon retest of those stains on day 65 and 78, respectively, the result was positive (Table 
7). Thus, both SEMG1 and PRM2 were detected by the ParaDNA® Body Fluid ID Test 
in room temperature stains up to 101 days, although false negative results were 
sometimes obtained. These results contradict a study that performed reverse transcription 
and quantification with the RiboGreen® detection dye (Molecular Probes, Eugene, OR) 
fluorescence assay, real-time PCR and gel electrophoresis on semen samples stored in the 
exact same manner as this study and detected the PRM2 marker for only up to 30 days 
[34]. A separate study, however, detected the PRM2 marker in dried 5 µL semen stains 
stored at room temperature and exposed to daylight for up to 72 weeks using the EZ1 
robot for extraction followed by reverse transcription and quantification with the 
iScript™ cDNA Synthesis kit (Bio-Rad, Hercules, CA, USA), endpoint PCR and 
capillary electrophoresis [35]. Other studies utilized real-time and endpoint PCR and 
capillary electrophoresis to detect PRM2 in 2 year-old stains that were stored in a dry 
dark place and both SEMG1 and PRM2 in two out of five 28 year-old stains [18, 19]. 
Furthermore, SEMG1 did not show any sign of degradation in 50 µL semen stains stored 
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in the dark at room temperature for six months after RNA extraction and quantification 
with PCR [36]. The results from the present study indicate that the ParaDNA® Body 
Fluid ID Test is able to detect both PRM2 and SEMG1 in approximately 3 month-old 
semen stains stored in room temperature away from light; it is possible that even older 
stains may have been detectable had the age study continued. 
Although both markers were detected at 101-days, the fact that 4 out of 14 
samples (29%) yielded false negative results cannot be ignored. During the course of the 
study, the 30-second sampling time was increased to 45 seconds at the suggestion of 
LGC (personal communication). Three of the four false negative results occurred prior to 
this change in protocol, but even after this 15-second increase in sampling time, a false 
negative was obtained on Day 78 (Table 7).  
These false negative samples illustrate the variability introduced in the sampling 
process and therefore the repeatability and reproducibility of sampling with the 
ParaDNA® Sample Collector comes into question. The sample collector has a nib at the 
end of each of the four prongs designed to collect particles from the stain. After 
sampling, the four prongs are oriented into the test plate containing the required PCR 
reagents and primers and the plate is sealed. However, not all six primers for each body 
fluid are in each of the four wells. Three of the six primers are in two wells and the other 
three primers are in the remaining diametrically opposite wells (Figure 4). This set-up is 
designed to decrease the chance of false negative results through uneven distribution of 
sample on the sample collector and therefore highlights the importance of the even 
rotation of the sampling device during collection [37].  
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Figure 4. Placement of RNA marker primers within ParaDNA® Body Fluid ID Test 
plate wells 
 
However, based on the false negative results from this study, it is clear this design 
has not been completely optimized to prevent false negative results. Therefore, it is 
recommended that repeatability and reproducibility of the sampling procedure with the 
ParaDNA® Sample Collector be thoroughly validated within a laboratory during the 
implementation process.  
 
4.4 Ten Freeze-Thaw Cycles 
 The goal of this phase of the experiment was to determine if multiple freeze-thaw 
cycles at approximately -20°C have an effect on the stability of the PRM2 and SEMG1 
RNA markers and thus the ability of the ParaDNA® Systems Body Fluid ID Test to 
detect them. Stability of RNA with different storage temperatures and in different forms 
such as liquid extracts, dried stains, and whole samples has been heavily researched, 
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specifically with human blood samples. In liquid whole blood samples stored at -20°C, 
only a 20% yield of the original RNA content was detected after 30 days [38]. Similarly, 
a study that quantified RNA in whole blood samples stored at 4°C and -80°C found 
significant decreases between samples stored for just 24, 32, and 40 hours. Significant 
declines in RNA concentration were not only detected among samples differing in 
storage time but also between the two storage temperatures, thus authors recommended 
whole blood samples only to be stored at -80°C [39]. It is well established that RNA 
within whole samples or extracts is best protected from degradation when stored between 
-70°C and -80°C [40-43].  
Research has been performed to determine if there are any differences in RNA 
degradation with samples stored as dried stains. Dried blood spots positive for Hepatitis 
C virus (HCV) were stored at room temperature, 4°C, -20°C, and -80°C for 12 months 
and RNA was quantified on a weekly/monthly basis. No significant changes between 
tests in each temperature group or among the four storage temperatures were observed 
[44]. These results coincide with a study that found detectable amounts of RNA using 
PCR in whole blood stains dispersed on cotton swabs stored at -80°C for up to 180 days 
[45]. While these studies researched RNA stability in blood samples and not semen and 
therefore are not specific to the current study at hand, it seems reasonable to apply these 
same concepts to RNA stability within any bodily fluid. These data suggest that it’s 
possible the RNA experiences less degradation when it is in a dried form as opposed to 
when stored in whole form exposed to other cellular components and enzymes. This 
would be advantageous with the use of the ParaDNA® Body Fluid ID Test in forensic 
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laboratories as the majority of evidence that requires body fluid identification is in the 
form of a dried stain, and therefore will most likely retain detectable amounts of RNA. 
That being said, the significant RNA degradation that appears to occur in whole samples 
while refrigerated and/or frozen may introduce an issue during the ParaDNA® Systems 
implementation process into a forensic laboratory as internal validation studies may be 
performed with in-house frozen samples stored specifically for validation and research. 
Therefore, there was an investigation into the possibility of frozen storage of neat semen 
samples and multiple freeze-thaw cycles having a negative effect on the detection of the 
RNA markers of the ParaDNA® Body Fluid ID Test.  
 PRM2 and SEMG1 were detected by the ParaDNA® Body Fluid ID Test for up 
to ten freeze-thaw cycles. Both markers were also positively detected in all eleven of the 
dried stains stored at room temperature and all of the ten stains prepared using the 
individually frozen aliquots (Table 8). These results appear to coincide with other 
experiments investigating freeze-thaw cycles and their effect on RNA degradation. One 
study investigated the effects of storage temperature and multiple freeze-thaw cycles at -
80°C on the influenza RNA quantity in extracts. Researchers only found a significant 
decrease in RNA quantity after the tenth freeze-thaw cycle, but the virus was still 
detectable at all cycles [41]. Similarly, another research study exposed RNA extracts 
from bovine reproductive tissue to 1, 2, 4, or 6 freeze-thaw cycles also at -80°C. There 
was no loss of RNA in samples exposed up to 6 cycles [40]. It is important to note that in 
these two studies pure RNA extracts were exposed to freeze-thaw cycles, possibly 
isolating the RNA from any other enzymes or biochemical processes in whole samples 
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that could degrade it. Investigations have also been performed to study effects of freeze-
thaw samples in more complete samples, such as in blood plasma and serum samples as 
well as cell-free seminal fluid samples. There was no significant loss in HCV RNA 
stability in either blood plasma or serum samples from 10 patients after 10 freeze-thaw 
cycles at -80°C [46].  An examination into the stability of RNA in semen samples after 
multiple freeze-thaw cycles appears to be limited. However, one study found no 
significant loss of human immunodeficiency virus type one (HIV-1) RNA concentration 
in two cell-free seminal fluid samples for up to four freeze-thaw cycles at -70°C [47]. 
 The data from the freeze-thaw portion of this investigation into the ParaDNA® 
Systems Body Fluid ID Test indicate that the PRM2 and SEMG1 RNA markers for 
sperm cells and seminal fluid, respectively, are robust and do not appear to be easily 
susceptible to potential RNA degradation introduced by multiple freeze-thaw cycles. This 
is an important finding, as laboratories may use frozen samples that have undergone 
multiple freeze-thaw cycles either in casework or as to validate this instrument during the 
implementation process.   
 
4.5. Post-Coital Swabs  
 Spermatozoa and seminal fluid were detected by the ParaDNA® Body Fluid ID 
Test in 8 out of 9 trials of the three post-coital swabs. Vaginal fluid was also detected in 4 
of the 8 successful runs (Tables 9-11). When the conventional semen screening 
methodology was performed three times for each post-coital swab, both sperm cells and 
seminal fluid were detected in all nine trials. The major difference between the two 
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techniques is that the conventional semen screening method is unable to distinguish 
seminal acid phosphatase and vaginal acid phosphatase, whereas the ParaDNA® Body 
Fluid ID Test has that capability. In instances where seminal fluid and spermatozoa are 
also detected, this difference may not be of importance. However, there are certain 
situations where this would be advantageous. For example, during the conventional 
semen screening of a sexual assault swab, an analyst may obtain a positive result for acid 
phosphatase but upon secondary screening with a microscopic examination and PSA or 
Sg testing, results are negative. In this example, time and resources have been wasted on 
a sample that could consist solely of vaginal fluid. If the ParaDNA® Body Fluid ID Test 
was used after the acid phosphatase screen instead, the body fluid(s) present would be 
identified more efficiently.  
 The comparison between the ParaDNA® Body Fluid ID Test and the 
conventional semen screening methodology for post-coital swabs is significantly 
different than what was observed in the sensitivity studies I and II. In the sensitivity 
studies, the ParaDNA® Body Fluid ID Test appeared less sensitive than the conventional 
screening method, as it was unable to detect spermatozoa and seminal fluid in 1:10 
diluted samples while conventional methods detected both components in 1:10 and 1:50 
samples. For the post-coital swabs, spermatozoa and seminal fluid were detected by both 
methods in all of the nine trials except for one, in which the ParaDNA® Body Fluid ID 
Test was unable to detect neither spermatozoa, seminal fluid, or vaginal fluid but 
conventional screening detected sperm cells and seminal fluid (Table 9). Epithelial cells 
were also observed in all nine trials using the conventional screening method. These 
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results indicate that the ParaDNA® Body Fluid ID Test has the potential to be a 
successful tool in the testing of post-coital swabs, and could therefore be useful in the 
testing of sexual assault swabs in a forensic laboratory setting. Sampling of the swabs 
was relatively simple and in 90 minutes a confirmatory test for spermatozoa, seminal 
fluid, and vaginal fluid was obtained with little work done by the analyst.  
 
4.6 Proportion of Experimental False Negatives  
 The goal of this research was to investigate the abilities of the LGC ParaDNA® 
Body Fluid ID Test and which types of forensic samples that this instrument may perform 
best with or be advantageous over conventional semen screening protocols. Throughout 
the analysis, the sampling process was found to be relatively simple, quick, and easily 
teachable. Once sampling is completed, all that is required of the analyst is to seal the 
plate, place it into the instrument, and click the “Start” button and the ParaDNA® System 
completes the remainder of the testing. While these attributes are well appreciated in 
forensic testing, there was one major downfall of the ParaDNA® Body Fluid ID Test, 
and that was the proportion of samples that yielded a false negative result. A false 
negative result was defined as any sample that tested negative for either the sperm cell or 
seminal fluid RNA marker. Of the 82 samples known to contain both spermatozoa and 
seminal fluid tested with the ParaDNA® Body Fluid ID Test, 22 were negative for either 
one or both RNA markers, which results to approximately 27% of samples (Table 12). 
This is much different than the number of false negatives reported in LGC’s validation 
data, as they reported a 0% false negative rate for both sperm cells and seminal fluid out 
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of 21 and 24 samples, respectively [32]. While more than double the number of samples 
was analyzed in this research compared to LGC’s validation studies, this still appears to 
be a drastic difference.  
 
Table 12. Proportion of false negative samples  
 
Sample Type Number of False Negative Tests  
Dilution 11 
Age 4 
Freeze-Thaw 3 
Preliminary Testing 3 
Post-Coital Swab 1 
Total Number of False Negatives 22 
Total Number of Tests 82 
Proportion of False Negatives 27% 
 
 It is unknown exactly what caused these false negative results throughout the 
testing process, as there are a number of potential areas, such as the sample collection 
technique and sampling time, how the stains/liquid samples were stored, sealing of the 
plate, and the functionality of the instrument during the run. The fact that the researcher 
did not have as much experience with the sampling method and instrument as LGC 
scientists can potentially explain the difference in the number of false negative samples. 
That being said, results in Table 12 appear to illustrate a trend of false negatives when it 
comes to sample type. Of the 22 false negative samples, 11 of them were either 1:10 or 
1:50 diluted stains during the sensitivity studies, while only four were from the room 
temperature stains age study, three from source trials, three from freeze-thaw, and one 
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from post-coital swab testing (Table 12). The reason for this is not known, but it was 
learned that other external users of the ParaDNA® System have had difficulty with 
diluted samples (personal communication). One thing to note is that all of these samples 
in this study besides the post-coital swab were exposed to the same storage conditions. 
After each of these stains was prepared, the cotton swatches were stored in paper 
envelopes in the dark at room temperature. Perhaps these storage conditions have an 
effect on RNA stability of PRM2 and SEMG1 and an influence on the chance for false 
negative results. It may be interesting in the future to compare storage conditions, such as 
light vs. dark, freezing vs. room temperature, and paper vs. plastic containment to 
investigate their effect, if any, on the detection of PRM2 and SEMG1 by the ParaDNA® 
Body Fluid ID Test.  
 Of the 22 false negative tests, the four from the age study and 3 from the freeze-
thaw study (data not shown) were repeated, upon which both sperm and seminal fluid 
were detected in the samples. It is a surprising and concerning finding that 7 of the 22 
false negatives tested positive after a second test under the same or similar conditions. In 
terms of casework, that would be seven erroneously negative reports and therefore seven 
sexual assault cases that potentially go unsolved. LGC has designed raw data analysis 
software that uses melt curve analysis to further analyze the signal of each body fluid per 
well. Nine samples were externally analyzed with this software, of which eight samples 
showed evidence of below threshold peaks for the fluid that was negative. As the use of 
this software could illustrate the need for further testing and reduce the number of false 
negative results in a forensic laboratory, it detracts from the efficiency of testing.  
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 Twelve of the twenty-two false negatives were also tested using the conventional 
semen methodology described in section 2.3 in which sperm cells and seminal fluid were 
detected in all 12 samples. The question that arises is if the conventional method still 
works while the ParaDNA® Body Fluid ID Test appears to have a risk for false negative 
results, then why should a forensic laboratory implement the ParaDNA® System? An 
example of where the ParaDNA® Body Fluid ID Test may be useful in a forensic 
laboratory setting is the testing of sexual assault swabs, where a positive AP Spot test 
could mean either VAP or SAP and there is a negative microscopic examination for 
spermatozoa. Although immunoassay cartridges are utilized to test for seminal fluid after 
negative microscopic examinations, the ParaDNA® Body Fluid ID Test would test for 
both components in one test, diminishing the amount of time and resources devoted to the 
analysis of one sample. This could also be beneficial for the preservation of samples, as 
less of the sample is consumed. However, it is not recommended that the ParaDNA® 
Body Fluid ID Test replace conventional testing methodology because of the risk for 
false negatives illustrated in this research.  
 It is a possibility that the answer to reducing the false negative rate of the 
ParaDNA® Body Fluid ID Test is the use of other target RNA markers for the six body 
fluids. Research efforts into the use of RNA for confirmatory testing of biological fluids 
have involved investigation into robust and specific RNA markers that may be used to 
identify the common fluids encountered in biological evidence. In a study that 
investigated 13 possible RNA markers to detect a variety of body fluids, specifically 
PRM1 and PRM2 to target sperm, results showed that both RNA markers were specific 
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to semen, but PRM2 appeared to be more sensitive than PRM1 [18]. Another study 
analyzed the validity of SEMG1 and PRM1 in the detection of semen and found both 
markers were detectable in 0.05 µL stains, but PRM1 was only expressed in fertile men 
[19]. This data indicates the validity in using SEMG1 and PRM2 in the detection of 
semen. However, a more recent study investigated novel RNA markers, TNP1 for 
spermatozoa and KLK2 for seminal fluid, and compared them to PRM1/2 and SEMG1. 
TNP1 is involved in the elongating and condensing of DNA during spermatogenesis, 
while KLK2 is an enzyme produced in the prostate gland responsible for activating PSA 
[48, 49]. TNP1 demonstrated strong expression in the samples tested containing 
spermatozoa and was not detected in the six samples from azoospermic donors, 
illustrating specificity for sperm cells. However, it was detected in one saliva sample and 
one menstrual fluid sample, but researchers report that peaks disappeared upon 
reamplification, and were most likely due to contamination because of large body fluid 
volumes. Regarding KLK2, it was detected in all semen samples tested, including the 
ones from azoospermic donors, and was not detected in any of the other body fluids 
tested.  When the sensitivity of TNP1 was compared to that of PRM2, there was a 
statistically significant increase in detection of TNP1 than PRM2 [50]. These data 
suggest that KLK2 and TNP1 are also promising RNA markers for seminal fluid and 
spermatozoa, respectively, and it may be worthwhile for further comparisons between 
these and other potential markers and SEMG1 and PRM2, as they may provide for more 
robust markers for the ParaDNA® Body Fluid ID Test.  
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5. CONCLUSIONS 
 The purpose of this research project was to investigate the performance and 
sensitivity of the ParaDNA® Systems Body Fluid ID Test with semen samples and 
compare it to the current conventional semen screening methodology. The stability of the 
RNA markers specific to spermatozoa and seminal fluid were also evaluated through 
testing of room temperature aged stains and in semen subjected to ten freeze-thaw cycles. 
The results indicate that the ParaDNA® Body Fluid ID Test was unable to detect 
spermatozoa and seminal fluid in some 1:10 stains and not at all in 1:50 diluted stains, 
while the conventional method detected both components in all trials. However, PRM2 
and SEMG1 were detectable in neat room temperature stored stains for up to 101 days, in 
stains prepared with semen subjected to ten freeze-thaw cycles, and in 8 of 9 trials 
involving post-coital swabs, in which vaginal fluid was also detected. Approximately 
27% of all samples tested with the ParaDNA® Body Fluid ID Test gave false negative 
results the first time they were tested, the biggest downfall of the test.  
 This instrument cannot currently replace conventional screening methods. It was 
found overall to be less sensitive than AP Spot, PSA, and Sg testing and microscopy. The 
false negative rate also needs to be further investigated and corrected, which potentially 
may include improving the repeatability and reproducibility of the sampling technique 
with the ParaDNA® Sample Collector or through the use of new target RNA markers.  
The instrument and software are simple to use, the sampling technique is easily learned, 
and it is a 90-minute fully automated assay, leaving minimal work up to the analyst. 
Following further development and extensive validation, it is possible that the 
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ParaDNA® Systems Body Fluid ID Test by LGC could become a viable tool for forensic 
laboratories.  
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